Cancer therapy company Lantern Pharma Inc (NASDAQ: LTRN) announced on Monday that it has received FDA clearance for its investigational new drug (IND) application for LP-284, targeting the treatment of relapsed or refractory non-Hodgkin's lymphoma (NHL). The Phase 1 trial for LP-284 is set to begin enrollment in Q4 2023.
LP-284 is designed to preferentially damage cancer cells with mutations in DNA damage repair pathways.
NHL, a haematological malignancy, affects around 500,000 people globally annually. Despite advances in treatment, a significant percentage of patients relapse, making LP-284's estimated global market potential of USD4bn a significant opportunity for Lantern Pharma.
Lantern Pharma is an AI-driven company that aims to accelerate oncology drug discovery and development using its RADR platform, cutting costs and timelines. The company's growing pipeline, with a combined annual market potential of over USD15bn, includes therapies for multiple cancer indications.
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study